Goldman Sachs sets new Biogen stock price target on bold Alzheimer's bet
Quick Take
Goldman Sachs raises Biogen's stock price target amid its ambitious Alzheimer's drug development.
Key Points
- Goldman Sachs sets a new price target for Biogen.
- The adjustment reflects confidence in Alzheimer's treatment.
- Biogen is focusing on innovative drug solutions.
Reader Mode unavailable (could not extract clean content).
Want this in your inbox every morning?
Daily brief at your local 8am — bilingual EN/中文, free.
More from Yahoo Finance
See more →
2d ago
FeaturedOriginal
These Super Stocks Could Be the Biggest Winners in the AI Inference and Agentic AI Economy
AI Summary
The article highlights top stocks poised for growth in the AI inference and agentic AI sectors.
